Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma
Haihe Biopharma Co., Ltd. announced that its independently developed selective PI3Kα inhibitor, Risovalisib Mesylate Tablets,...
Haihe Biopharma
Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3Kα...
Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan
China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...
Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...
Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan
Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...
CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...